NASDAQ:MOLN Molecular Partners (MOLN) Stock Price, News & Analysis $3.55 -0.12 (-3.27%) As of 02:45 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Molecular Partners Stock (NASDAQ:MOLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Molecular Partners alerts:Sign Up Key Stats Today's Range$3.52▼$3.7050-Day Range$3.67▼$4.6152-Week Range$3.52▼$5.36Volume1,384 shsAverage Volume4,433 shsMarket Capitalization$143.35 millionP/E RatioN/ADividend YieldN/APrice Target$8.38Consensus RatingHold Company Overview Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland, and listed on Nasdaq under the symbol MOLN. The company develops targeted therapies using its proprietary DARPin platform, which is designed to create small, modular proteins that can bind selectively to disease-related targets and be engineered into multi-specific medicines. Molecular Partners’ research and development activities have focused primarily on oncology and immuno-oncology, including treatments intended to engage or modulate the immune system and address complex biological targets. The company has also developed antiviral candidates, including ensovibep, a DARPin-based therapy investigated for the treatment of COVID-19. Its pipeline has included internally developed programs as well as candidates advanced through collaborations with pharmaceutical and biotechnology companies. Founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH Zurich), Molecular Partners serves global pharmaceutical and biotechnology markets through research, clinical development and strategic partnerships. The company’s programs remain subject to clinical testing and regulatory review, and its focus may evolve as development priorities change.AI Generated. May Contain Errors. Read More Molecular Partners Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreMOLN MarketRank™: 2.014827450465 of 5 starsMolecular Partners scored higher than 40% of companies evaluated by MarketBeat, and ranked 689th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingMolecular Partners has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMolecular Partners has a consensus price target of $8.38, representing about 135.9% upside from its current price of $3.55.Amount of Analyst CoverageMolecular Partners has only been the subject of 1 research reports in the past 90 days.Read more about Molecular Partners' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Molecular Partners are expected to grow in the coming year, from ($1.28) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Molecular Partners is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Molecular Partners is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMolecular Partners has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Molecular Partners' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Molecular Partners has been sold short.Short Interest Ratio / Days to CoverMolecular Partners has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Molecular Partners has recently increased by 13.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMolecular Partners does not currently pay a dividend.Dividend GrowthMolecular Partners does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment0.61 News SentimentMolecular Partners has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Molecular Partners this week, compared to 2 articles on an average week. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Molecular Partners insiders have not sold or bought any company stock.Percentage Held by Insiders5.93% of the stock of Molecular Partners is held by insiders.Percentage Held by Institutions26.55% of the stock of Molecular Partners is held by institutions.Read more about Molecular Partners' insider trading history. Receive MOLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MOLN Stock News HeadlinesMolecular Partners (NASDAQ:MOLN) and Incyte (NASDAQ:INCY) Head to Head SurveyOctober 11 at 10:15 AM | americanbankingnews.comContrasting Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)October 7, 2026 | americanbankingnews.comINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.October 14 at 1:00 AM | Paradigm Press (Ad)Head to Head Review: AquaBounty Technologies (NASDAQ:AQB) and Molecular Partners (NASDAQ:MOLN)October 5, 2026 | americanbankingnews.comMolecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash BaseAugust 26, 2026 | theglobeandmail.comMolecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a StudyAugust 25, 2026 | globenewswire.comMolecular Partners Showcases Bispecific Radio-DARPins at Gordon Research ConferenceJuly 15, 2026 | globenewswire.comLifeSci Capital Sticks to Their Buy Rating for Molecular Partners (MOLN)July 12, 2026 | theglobeandmail.comSee More Headlines MOLN Stock Analysis - Frequently Asked Questions How have MOLN shares performed this year? Molecular Partners' stock was trading at $4.4450 at the start of the year. Since then, MOLN stock has decreased by 20.1% and is now trading at $3.55. How were Molecular Partners' earnings last quarter? Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) released its earnings results on Tuesday, August, 25th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01. When did Molecular Partners IPO? Molecular Partners (MOLN) raised $64 million in an initial public offering on the week of June 14th 2021. The company issued 3,000,000 shares at a price of $21.25 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager. How do I buy shares of Molecular Partners? Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Molecular Partners own? Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Partners investors own include Agenus (AGEN), Altimmune (ALT), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunityBio (IBRX), NVIDIA (NVDA) and Sangamo Therapeutics (SGMO). Company Calendar Last Earnings8/25/2026Today10/14/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (25m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MOLN's financial health is in the Red zone, according to TradeSmith. MOLN has been in this zone for over 25 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MOLN CIK1745114 Webwww.molecularpartners.com Phone41-44-755-7700FaxN/AEmployees134Year Founded2004Price Target and Rating Average Price Target for Molecular Partners$8.38 High Price Target$13.00 Low Price Target$3.75 Potential Upside/Downside+135.9%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-68.36% Return on Assets-54.82% Debt Debt-to-Equity RatioN/A Current Ratio7.27 Quick Ratio7.27 Sales & Book Value Annual Sales$5.65 million Price / Sales25.37 Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book1.48Miscellaneous Outstanding Shares40,380,000Free Float37,981,000Market Cap$143.35 million OptionableNot Optionable Beta1.11 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:MOLN) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredElon will prove them wrong againElon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no ...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MOLN Stock Alerts